| Literature DB >> 30625267 |
Ji Young Park1, Tae Joo Jeon1.
Abstract
BACKGROUND/AIMS: Pathological diagnosis of biliary strictures with atypical or suspicious cells on endoscopic retrograde brush cytology and indeterminate strictures on imaging is challenging. The aim of this study was to identify markers for malignant strictures in such cases.Entities:
Keywords: Atypical cell; Biliary stricture; Brush cytology; Suspicious cell
Year: 2019 PMID: 30625267 PMCID: PMC6453855 DOI: 10.5946/ce.2018.105
Source DB: PubMed Journal: Clin Endosc ISSN: 2234-2400
Basal Characteristics of the 146 Patients in Our Study
| Variables, | Value |
|---|---|
| Male gender | 86 (58.9) |
| Age (yr, mean±SD) | 66.9±12.6 |
| BMI (kg/m2, mean±SD) | 22.5±2.9 |
| Diabetes mellitus | 32 (21.9) |
| Smokers | 31 (21.2) |
| Alcoholic | 47 (32.2) |
| Clinical presentations | |
| GB/CBD stone | 69 (47.3) |
| Cholangitis | 100 (68.5) |
| Jaundice | 98 (67.1) |
| Weight loss | 25 (17.1) |
| Laboratory values (mean±SD) | |
| AST (U/L) | 169.9±223.3 |
| ALT (U/L) | 174.6±218.3 |
| ALP (U/L) | 312.0±295.4 |
| Total bilirubin (mg/dL) | 6.1±7.0 |
| rGT (U/L) | 437.4±422.8 |
| CEA (ng/mL) | 2.6±4.0 |
| CA19-9 (U/mL) | 1,219.2±2,800.2 |
| Elevated CA19-9 (>37 U/mL) | 85 (58.2) |
| Length of stricture (mm, mean±SD) | 19.8±15.7 |
| Location of stricture | |
| Upper third | 81 (55.5) |
| Middle third | 35 (24.0) |
| Lower third | 30 (20.5) |
| Final diagnosis | |
| Benign stricture | 79 (54.1) |
| Pancreatic cancer | 5 (3.4) |
| Cholangiocarcinoma | 48 (32.9) |
| AOV cancer | 5 (3.4) |
| GB cancer | 6 (4.1) |
| Others | 3 (2.1) |
| Detection of cancer | 67 (45.9) |
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AOV, ampulla of Vater; AST, aspartate aminotransferase; BMI, body mass index; CA19-9, carbohydrate antigen 19-9; CBD, common bile duct; CEA, carcinoembryonic antigen; GB, gallbladder; rGT, gamma-glutamyl transpeptidase; SD, standard deviation.
Brush Cytology Results
| Benign ( | Malignant ( | |
|---|---|---|
| No abnormal cells ( | 50 (63.3) | 19 (28.3) |
| Atypical cells ( | 25 (31.6) | 20 (29.9) |
| Suspicious cells ( | 4 (5.1) | 16 (23.9) |
| Malignant cells ( | 0 (0) | 12 (17.9) |
| Sensitivity | 71.6% (95% CI, 59.1–81.6) | |
| Specificity | 63.3% (95% CI, 51.6–73.6) | |
| Positive predictive value | 62.3% (95% CI, 51.1–72.3) | |
| Negative predictive value | 72.5% (95% CI, 60.5–81.6) | |
CI, confidence interval.
Univariate Comparisons between Benign and Malignant Biliary Strictures in Patients with Atypical or Suspicious Cells on Brush Cytology
| Benign ( | Malignant ( | ||
|---|---|---|---|
| Gender (male, %) | 14 (48.3) | 24 (66.7) | 0.107 |
| Age (yr, mean±SD) | 66.76±17.09 | 69.86±11.81 | 0.391 |
| Jaundice ( | 20 (69.0) | 30 (83.3) | 0.142 |
| Cholangitis ( | 23 (79.3) | 21 (58.3) | 0.109 |
| Weight loss ( | 4 (13.8) | 8 (22.2) | 0.294 |
| BMI (kg/m2) | 21.69±3.05 | 23.07±2.70 | 0.057 |
| GB stone ( | 14 (48.3) | 4 (11.1) | 0.002 |
| BD stone ( | 18 (62.1) | 3 (8.3) | 0.000 |
| Alcohol ( | 11 (37.9) | 10 (27.8) | 0.273 |
| Smoking ( | 3 (10.3) | 7 (19.4) | 0.256 |
| Diabetes mellitus ( | 4 (13.8) | 9 (25.0) | 0.210 |
| Laboratory values (mean±SD) | |||
| AST (U/L) | 202.97±166.90 | 158.72±144.16 | 0.256 |
| ALT (U/L) | 202.41±189.82 | 169.38±153.09 | 0.448 |
| ALP (U/L) | 231.45±163.68 | 411.75±285.57 | 0.004 |
| total bilirubin (mg/dL) | 3.23±2.29 | 8.70±8.48 | 0.001 |
| rGT (U/L) | 312.91±271.02 | 596.72±527.17 | 0.011 |
| CEA (ng/mL) | 1.49±1.78 | 3.96±5.34 | 0.017 |
| CA19-9 (U/mL) | 91.02±272.22 | 1,682±3,155.64 | 0.005 |
| Length of stricture (mm, mean±SD) | 14.86±14.83 | 25.83±15.33 | 0.005 |
| Location of stricture (lower/mid/upper, %) | 10.3/31.0/58.6 | 27.8/25.0/47.2 | 0.145 |
| Upstream bile duct diameter (mm, mean±SD) | 11.0±3.5 | 13.0±4.3 | 0.449 |
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BD, bile duct; BMI, body mass index; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; GB, gallbladder; rGT, gamma-glutamyl transpeptidase; SD, standard deviation.
Variables Associated with Malignant Strictures
| odds ratio | 95% CI | ||
|---|---|---|---|
| GB stone | 0.134 | 0.038–0.477 | 0.002 |
| BD stone | 0.056 | 0.014–0.225 | 0.000 |
| CA19-9 | 3.492 | 1.242–9.815 | 0.018 |
| CEA | 4.909 | 1.694–14.224 | 0.003 |
| t.Bil | 2.506 | 0.918–6.842 | 0.073 |
| ALP | 3.362 | 1.207–9.361 | 0.020 |
| rGT | 4.318 | 1.521–12.262 | 0.006 |
| Length of stricture | 5.250 | 1.802–15.294 | 0.002 |
ALP, alkaline phosphatase; BD, bile duct; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CI, confidence interval; GB, gallbladder; rGT, gamma-glutamyl transpeptidase; t.Bil, total bilirubin.
Fig. 1.Receiver operator curves and corresponding area under curves for carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (rGT) and length of stricture.
The Optimal Cut-Off Values of CA19-9, CEA, ALP, rGT and Length of Stricture
| AuC (95% CI) | Cut-off value | Sensitivity | Specificity | ||
|---|---|---|---|---|---|
| CA19-9 | 0.729 (0.649–0.811) | 56.44 U/mL | 73.1% | 64.6% | 0.000 |
| CEA | 0.750 (0.673–0.828) | 1.51 ng/mL | 79.1% | 58.7% | 0.000 |
| ALP | 0.736 (0.654–0.817) | 200.5 U/L | 76.1% | 60.8% | 0.000 |
| rGT | 0.706 (0.620–0.791) | 297.0 U/L | 74.6% | 63.3% | 0.000 |
| Length of stricture | 0.791 (0.717–0.865) | 14.5 mm | 74.6% | 74.7% | 0.000 |
ALP, alkaline phosphatase; AUC, area under curve; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CI, confidence interval; rGT, gamma-glutamyl transpeptidase.